Acute Myeloid LeukemiaPhase 1NCT04219163
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
A Phase 1 study testing CLL-1.CAR T cells in people with Acute Myeloid Leukemia, run by Baylor College of Medicine at 2 sites in United States.
Trial summary
Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and T cells with the… Read more about this study
- Who is it for?
- Ages Up to 75 years
- Conditions the study is for
- Acute Myeloid Leukemia
- What is being tested?
- CLL-1.CAR T cells
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 2 sitesUnited States
- Study dates
- 9 Jul 2020to 31 Jul 2038
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) with the exception of acute promyelocytic leukemia (APL) AND suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation of an identified eligible donor by a FACT accredited transplant center
- CLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory
- Age ≤75 years NOTE: The first six (6) patients treated on the study will be adults (≥18 yrs of age).
- Hgb ≥ 7.0 g/dL(can be transfused)
- Life expectancy greater than 12 wks
- If apheresis required to collect blood
Show all 23Show fewer
- PT and APTT <1.5x ULN
- Serum Creatinine < 1.5 x ULN
- AST < 1.5 x ULN
- Informed consent
- Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) with the exception of acute promyelocytic leukemia (APL). Patients with targetable mutations should have failed or be ineligible for targeted therapies (e.g. FLT3 inhibitors, IDH inhibitors, or anti-CD33 drug conjugate). AND patients should be suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation of an identified eligible donor by a FACT accredited transplant center and with confirmation that the center plans to proceed with transplant if CLL-1.CAR treatment induces a response they consider adequate to proceed to allogeneic HSCT.
- CLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory
- Age ≤75 years NOTE: The first six (6) patients treated on the study will be adults (≥18 yrs of age).
- AST/ALT less than 5 times the upper limit of normal
- Bilirubin less than 3 times the upper limit of normal
- Estimated GFR ≥ 60ml/min
- Pulse oximetry of > 92% on room air
- Karnofsky/Lansky ≥ 60
- No systemic chemotherapy at least 2 weeks prior to treatment on study and must be recovered from all acute toxic effects of prior chemotherapy at time of treatment
- Available autologous transduced activated peripheral blood T-cell product with ≥ 20% expression of CLL-1.CAR.28z by flow cytometry
- Life expectancy > 12 weeks
- Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom
- Informed consent explained to, understood by, and signed by patient/guardian. Patient/guardian given copy of informed consent.
Who cannot join
- Diagnosis of acute promyelocytic leukemia (APL)
- Active infection (bacterial, fungal or viral) requiring ongoing treatment without improvement.
- Active infection with HIV or HTLV (results may be pending)
- Active second cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer)or other cancer treated ≤ 2 years prior to enrollment
- Ongoing treatment with immune suppression for prophylaxis or treatment of GVHD including high dose steroids (e.g. prednisone > 0.25mg/kg)
- TREATMENT
Show all 20Show fewer
- Diagnosis of acute promyelocytic leukemia (APL)
- Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks.
- History of hypersensitivity reactions to murine protein-containing products.
- Pregnant or lactating.
- Active infection with HIV or HTLV.
- Clinically significant bacterial, viral or fungal infection requiring ongoing antifungal therapy without improvement,.
- Fever of unknown origin without complete work-up including imaging (CT head, sinus, chest, abdomen/pelvis)
- Cardiac criteria: Prolonged QTc with maximum interval as defined by age; Uncontrolled atrial fibrillation/flutter; Myocardial infarction; Cardiac echocardiography with LVSF<30% or LVEF<50% or clinically significant pericardial effusion; Cardiac dysfunction NYHA III or IV; Confirmation of absence of these conditions within 6 months of treatment.
- CNS abnormalities: Presence of CNS disease defined as detectable cerebrospinal blast cells in a sample of CSF with ≥ 5 WBCs per mm^3 or chloroma on imaging, History or presence of an underlying CNS disorder such as a seizure disorder requiring current use of antiepileptic medications, cerebrovascular ischemia/hemorrhage within prior 6 months, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
- Use of serotherapy with Campath or Anti-Thymocyte Globulin (ATG) within the last 28 days
- Use of Donor Lymphocyte Infusion (DLI) or other cellular therapy product within 30 days
- Acute GVHD ≥ Grade 2 or moderate to severe (formerly extensive) chronic GVHD
- Administration of high dose steroids >1 mg/kg within the preceding 5 days or currently receiving > 0.25 mg/kg of Prednisone equivalent
- Hyperleukocytosis (WBC ≥50K) or rapidly progressive disease that in the estimation of the investigator would compromise the ability of the patient to complete the study.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Houston Methodist Hospital
Houston, Texas, 77030
Texas Children's Hospital
Houston, Texas, 77030
About this study
Official title: Chimeric Antigen Receptor T-cells for The Treatment of Acute Myeloid Leukemia Expressing CLL-1 Antigen
Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment.
The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and T cells with the hope that they will work together. T cells (also called T lymphocytes) are special infection-fighting blood cells that can kill other cells including tumor cells. Antibodies are types of proteins that protect the body from bacterial and other infectious diseases. Both antibodies and T cells have been used to treat patients with cancers; they have shown promise, but have not been strong enough to cure most patients when used alone.
Read more
T lymphocytes can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person. The antibody used in this study targets CLL-1. This antibody sticks to AML cells because of a substance (protein) on the outside of these cells called CLL-1. For this study, the antibody to CLL-1 has been changed so that instead of floating free in the blood, it is now joined to the T cells. When T-cells contain an antibody that is joined to them, they are called chimeric antigen receptor T-cells or CAR-T cells.
In the laboratory, the investigators have also found that T cells work better if proteins that stimulate T cells are also added, such as one called CD28. Adding the CD28 makes the cells grow better and last longer in the body, thus giving the cells a better chance of killing the leukemia or lymphoma cells. In this study we are going to attach the CLL-1 chimeric receptor that has CD28 added to it to the patient's T cells. We will then test how long the cells last.
These CLL-1 chimeric antigen receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.
Read the detailed description
To make the CLL1-CD28 chimeric antigen receptor T cells, the investigators will collect the patient's blood and stimulate them with growth factors to make the cells grow. To get the CLL-1 antibody and CD28 to attach to the surface of the T cell, we put the antibody gene into the T cell. This is done using a virus called a retrovirus that has been made for this study and will carry the antibody gene into the T cell. This virus also helps investigators find the T cells in the patient's blood after they are injected. Because the patient will receive cells with a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects of gene transfer.
When the patient enrolls on this study, the patient will be assigned a dose of CLL-1 chimeric antigen receptor- T cells. Several studies suggest that the T cells that we give to the patient need room to be able to grow and work well and that this may not happen if there are too many other T cells already circulating in the patient's body. Because of that, the patient will receive two chemotherapy medications before receiving the CLL-1 chimeric antigen receptor- T cells.
One medication is called cyclophosphamide and and the other will be either fludarabine or clofarabine. The patient will receive 3 daily doses of each drug, finishing at least one day before receiving the chimeric antigen receptor- T cells. These drugs will lower the numbers of the patient's T cells before we give them the CLL-1 chimeric antigen receptor T cells and will also help lower the number of other cells that may block the chimeric antigen receptor-T cells from working well. Although we do not expect any effect on the patient's cancer with the doses that will be received, these drugs are part of many treatment plans that are used to treat leukemia.
Patients will be given an injection of cells into the vein through an IV at the assigned dose at a minimum of 24 hours after completing the chemotherapy medications. The injection will take from 1 to 10 minutes. Before patients receive the injection, they may be given a dose of Benadryl and Tylenol. The treatment will be given by the Center for Cell and Gene Therapy at Texas Children's Hospital or Houston Methodist Hospital.
If the patient is one of the first set of enrolled patients, they will be admitted as an inpatient for at least 72 hours so that the doctor and nurses can watch them closely in case any potential side effects occur following infusion. After discharge from the hospital you will be followed closely in the clinic, and will have to remain in the Houston area for at least 4 weeks after the infusion. If patients have any side effects, they may have to be admitted to the hospital for evaluation and management. If after a 4 week evaluation period following the infusion, the patient has achieved a complete response, his/her cancer doctors may decide if you should go on to have a bone marrow transplant, at which time the patient will be removed from the treatment portion of the study
BEFORE BEING TREATED, PATIENTS WILL RECEIVE A SERIES OF STANDARD MEDICAL TESTS:
- Physical exam and History
- Blood tests to measure blood cells, kidney and liver function
- Pregnancy test for female patients who are of child bearing potential -Measurements of your tumor by bone marrow studies
- Imaging such as PET scans, CT scans or MRIs will be obtained if needed
PATIENTS WILL RECEIVE STANDARD MEDICAL TESTS DURING TREATMENT AND AFTER:
- Physical exams and History
- Blood tests to measure blood cells, kidney and liver function
- Measurements of your tumor by bone marrow studies 4-6 weeks after the infusion, possibly 12 weeks after the infusion and then per standard of care.
- Imaging such as PET scans, CT scans or MRIs will be obtained if needed 4-6 weeks following the infusion
To learn more about the way the CLL-1 chimeric receptor-T cells are working and how long they last in the body, extra blood will be drawn. The total amount on any day is about 10 teaspoons (50 mL) or no more than 3 mL per 2.2 pounds body weight in children. This amount is considered safe but may be lowered if you are anemic. This blood may be taken from a central line if you have one. Blood will be taken before the chemotherapy drugs, before the T cell infusion, several hours after the T cell infusion, at 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, and 8 weeks after the infusion, at 3 months, 6 months, 9 months, at 1 year, every 6 months for 4 years, then yearly for a total of 15 years.
If patients have a bone marrow exam while they are on this study, we may ask to have a sample of bone marrow to look for CLL-1 chimeric receptor- T cells.
If a patient decides to withdraw at any time during the study, both samples and data collected during his/her participation will be kept.
- Conditions
- Acute Myeloid Leukemia
- Being tested
- CLL-1.CAR T cells
- Keywords
- AML
- Medical subject headings
- Leukemia, Myeloid, Acute
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CLL-1.CAR T cellsBiological
Dose escalation study with 3 dose levels:
DL1: 1x10^7 cells/m2, DL2: 3x10^7 cells/m2, DL3: 1x10^8 cells/m2
If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10^6 cells/m2
| Study group | Role | What they receive |
|---|---|---|
| CLL-1.CAR | Experimental | Group A Receives: Biological: CLL-1.CAR T cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose limiting toxicity (DLT) rate
To assess dose limiting toxicities per protocol-defined CLL-1.CAR T related adverse events and CTCAE v5.0
Measured: 4 weeks post T cell infusion
Secondary outcomes (1)
Overall Response Rate
To measure the anti-tumor effects of CLL-1.CAR T-cells in patients with acute myeloid malignancies.
Measured: 4 weeks post T cell infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2020
- Study start9 Jul 2020
- Primary completion24 Mar 2025
- Study completion31 Jul 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myeloid LeukemiaStudies of the same condition, open and under way.
- More trials run by Baylor College of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
- Responsible party
- Principal investigator, Erin Doherty, Baylor College of Medicine
- Investigators
- LaQuisa Hill, MD, Principal investigator, Cell and Gene Therapy, Baylor College of MedicineErin Doherty, MD, Principal investigator, Baylor College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04219163
- Sponsor's protocol ID
- H-43516-CARMEN
- Other IDs
- 52988-C1
- Status last verified
- Sep 2026
- First submitted
- 3 Jan 2020
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chimeric Antigen Receptor T-cells for The Treatment of Acute Myeloid Leukemia Expressing CLL-1 Antigen
- ClinicalTrials.gov ID
- NCT04219163
- Acronym / sponsor ID
- H-43516-CARMEN
- Conditions
- Acute Myeloid Leukemia
- Keywords
- AML
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- Baylor College of MedicineUniversity, hospital or other
- Collaborators
- The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
- Study start
- 9 Jul 2020 (actual)
- Primary completion
- 24 Mar 2025 (actual)
- Study completion
- 31 Jul 2038 (estimated)
- First posted
- 6 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment.
The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and T cells with the hope that they will work together. T cells (also called T lymphocytes) are special infection-fighting blood cells that can kill other cells including tumor cells. Antibodies are types of proteins that protect the body from bacterial and other infectious diseases. Both antibodies and T cells have been used to treat patients with cancers; they have shown promise, but have not been strong enough to cure most patients when used alone.
T lymphocytes can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person. The antibody used in this study targets CLL-1. This antibody sticks to AML cells because of a substance (protein) on the outside of these cells called CLL-1. For this study, the antibody to CLL-1 has been changed so that instead of floating free in the blood, it is now joined to the T cells. When T-cells contain an antibody that is joined to them, they are called chimeric antigen receptor T-cells or CAR-T cells.
In the laboratory, the investigators have also found that T cells work better if proteins that stimulate T cells are also added, such as one called CD28. Adding the CD28 makes the cells grow better and last longer in the body, thus giving the cells a better chance of killing the leukemia or lymphoma cells. In this study we are going to attach the CLL-1 chimeric receptor that has CD28 added to it to the patient's T cells. We will then test how long the cells last.
These CLL-1 chimeric antigen receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.
Detailed description
To make the CLL1-CD28 chimeric antigen receptor T cells, the investigators will collect the patient's blood and stimulate them with growth factors to make the cells grow. To get the CLL-1 antibody and CD28 to attach to the surface of the T cell, we put the antibody gene into the T cell. This is done using a virus called a retrovirus that has been made for this study and will carry the antibody gene into the T cell. This virus also helps investigators find the T cells in the patient's blood after they are injected. Because the patient will receive cells with a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects of gene transfer.
When the patient enrolls on this study, the patient will be assigned a dose of CLL-1 chimeric antigen receptor- T cells. Several studies suggest that the T cells that we give to the patient need room to be able to grow and work well and that this may not happen if there are too many other T cells already circulating in the patient's body. Because of that, the patient will receive two chemotherapy medications before receiving the CLL-1 chimeric antigen receptor- T cells.
One medication is called cyclophosphamide and and the other will be either fludarabine or clofarabine. The patient will receive 3 daily doses of each drug, finishing at least one day before receiving the chimeric antigen receptor- T cells. These drugs will lower the numbers of the patient's T cells before we give them the CLL-1 chimeric antigen receptor T cells and will also help lower the number of other cells that may block the chimeric antigen receptor-T cells from working well. Although we do not expect any effect on the patient's cancer with the doses that will be received, these drugs are part of many treatment plans that are used to treat leukemia.
Patients will be given an injection of cells into the vein through an IV at the assigned dose at a minimum of 24 hours after completing the chemotherapy medications. The injection will take from 1 to 10 minutes. Before patients receive the injection, they may be given a dose of Benadryl and Tylenol. The treatment will be given by the Center for Cell and Gene Therapy at Texas Children's Hospital or Houston Methodist Hospital.
If the patient is one of the first set of enrolled patients, they will be admitted as an inpatient for at least 72 hours so that the doctor and nurses can watch them closely in case any potential side effects occur following infusion. After discharge from the hospital you will be followed closely in the clinic, and will have to remain in the Houston area for at least 4 weeks after the infusion. If patients have any side effects, they may have to be admitted to the hospital for evaluation and management. If after a 4 week evaluation period following the infusion, the patient has achieved a complete response, his/her cancer doctors may decide if you should go on to have a bone marrow transplant, at which time the patient will be removed from the treatment portion of the study
BEFORE BEING TREATED, PATIENTS WILL RECEIVE A SERIES OF STANDARD MEDICAL TESTS:
- Physical exam and History
- Blood tests to measure blood cells, kidney and liver function
- Pregnancy test for female patients who are of child bearing potential -Measurements of your tumor by bone marrow studies
- Imaging such as PET scans, CT scans or MRIs will be obtained if needed
PATIENTS WILL RECEIVE STANDARD MEDICAL TESTS DURING TREATMENT AND AFTER:
- Physical exams and History
- Blood tests to measure blood cells, kidney and liver function
- Measurements of your tumor by bone marrow studies 4-6 weeks after the infusion, possibly 12 weeks after the infusion and then per standard of care.
- Imaging such as PET scans, CT scans or MRIs will be obtained if needed 4-6 weeks following the infusion
To learn more about the way the CLL-1 chimeric receptor-T cells are working and how long they last in the body, extra blood will be drawn. The total amount on any day is about 10 teaspoons (50 mL) or no more than 3 mL per 2.2 pounds body weight in children. This amount is considered safe but may be lowered if you are anemic. This blood may be taken from a central line if you have one. Blood will be taken before the chemotherapy drugs, before the T cell infusion, several hours after the T cell infusion, at 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, and 8 weeks after the infusion, at 3 months, 6 months, 9 months, at 1 year, every 6 months for 4 years, then yearly for a total of 15 years.
If patients have a bone marrow exam while they are on this study, we may ask to have a sample of bone marrow to look for CLL-1 chimeric receptor- T cells.
If a patient decides to withdraw at any time during the study, both samples and data collected during his/her participation will be kept.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CLL-1.CAR | Experimental | Biological: CLL-1.CAR T cellsGroup A |
Who may qualify
- Ages
- Up to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (23 listed)
- Diagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) with the exception of acute promyelocytic leukemia (APL) AND suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation of an identified eligible donor by a FACT accredited transplant center
- CLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory
- Age ≤75 years NOTE: The first six (6) patients treated on the study will be adults (≥18 yrs of age).
- Hgb ≥ 7.0 g/dL(can be transfused)
- Life expectancy greater than 12 wks
Key exclusion criteria (20 listed)
- Diagnosis of acute promyelocytic leukemia (APL)
- Active infection (bacterial, fungal or viral) requiring ongoing treatment without improvement.
- Active infection with HIV or HTLV (results may be pending)
- Active second cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer)or other cancer treated ≤ 2 years prior to enrollment
- Ongoing treatment with immune suppression for prophylaxis or treatment of GVHD including high dose steroids (e.g. prednisone > 0.25mg/kg)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CLL-1.CAR T cellsDose escalation study with 3 dose levels: DL1: 1x10^7 cells/m2, DL2: 3x10^7 cells/m2, DL3: 1x10^8 cells/m2 If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10^6 cells/m2 | Biological | CLL-1.CAR |
Primary outcome
Dose limiting toxicity (DLT) rate
Time frame: 4 weeks post T cell infusion
To assess dose limiting toxicities per protocol-defined CLL-1.CAR T related adverse events and CTCAE v5.0
1 secondary outcome
Overall Response Rate
Time frame: 4 weeks post T cell infusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Myeloid Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 1/2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
LaQuisa Hill, MD principal investigator
Cell and Gene Therapy, Baylor College of Medicine
Erin Doherty, MD principal investigator
Baylor College of Medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing CLL-1.CAR T cells in people with Acute Myeloid Leukemia, run by Baylor College of Medicine at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 23 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose limiting toxicity (DLT) rate (time frame: 4 weeks post T cell infusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.